[
  {
    "ts": null,
    "headline": "Jim Cramer’s Take on Eli Lilly and Company (LLY): Bold Predictions for the Future",
    "summary": "We recently compiled a list of the Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been one of Jim Cramer’s favorite topics […]",
    "url": "https://finnhub.io/api/news?id=90699ea88d2a1989666eda449ad28f9e50a9c55657b143fee5f8207bd59f95ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735754153,
      "headline": "Jim Cramer’s Take on Eli Lilly and Company (LLY): Bold Predictions for the Future",
      "id": 132230072,
      "image": "https://media.zenfs.com/en/insidermonkey.com/a6c6a869a7c2c92171425bdb9b9fb0f6",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been one of Jim Cramer’s favorite topics […]",
      "url": "https://finnhub.io/api/news?id=90699ea88d2a1989666eda449ad28f9e50a9c55657b143fee5f8207bd59f95ac"
    }
  },
  {
    "ts": null,
    "headline": "Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.",
    "summary": "For pharmaceutical stocks, there are few events as crucial as the results of clinical trials for new drugs.",
    "url": "https://finnhub.io/api/news?id=984f6cf4667c8292801aeb8ca49ba050a3881af711ca3316be8e22fcd3ce6d96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735720200,
      "headline": "Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.",
      "id": 132225133,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "For pharmaceutical stocks, there are few events as crucial as the results of clinical trials for new drugs.",
      "url": "https://finnhub.io/api/news?id=984f6cf4667c8292801aeb8ca49ba050a3881af711ca3316be8e22fcd3ce6d96"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Be Greedy When Others Are Fearful",
    "summary": "Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=ec4cf43d993d992d0a95bf0f5ee033ac96f0bee59ddfcfe8164898129b750b85",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735701071,
      "headline": "Novo Nordisk: Be Greedy When Others Are Fearful",
      "id": 132224196,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/946624842/image_946624842.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=ec4cf43d993d992d0a95bf0f5ee033ac96f0bee59ddfcfe8164898129b750b85"
    }
  }
]